DCK and cancer: A dCK variant that could preferentially phosphorylate nucleoside analogues with respect to the natural substrate deoxycytidine, and therefore induce cell suicide upon exposure to low concentrations of prodrug, would constitute a good candidate for these “suicide gene” therapies in cancer treatment, but also in transplantation medicine.